Permeability of various drugs across the blood-brain barrier (BBB) is significantly dependent on the expression and functional activity of specific efflux transporters located in the membrane of brain capillary endothelial cells (BCEC). Selective transient downregulation of the transporters will lead to the application of more effective and less toxic doses of therapeutic drugs against brain tumors or viral infections in CNS. Previously, antisense inhibitors have been shown to temporarily arrest the synthesis of major multidrug resistance agent, membrane P-glycoprotein, and promote reversal of the resistant cell phenotype. The more effective RNA interference mechanism has been recently discovered for selective switching off expression of various genes. Short hairpin RNA (siRNA) could be introduced into target cells through a plasmid DNA precursor using methods of non-viral gene therapy. However, targeted delivery of the pDNA to the cells of the BBB requires a good systemic carrier and selective vectors that bind to the BCEC. As such a carrier, polymer crosslinked Nanogel particles modified with the brain-specific homing peptides (BSHP) have been chosen for tranfection of the BBB by shRNA-encoding plasmid DNA with an ultimate goal suppressing the specific membrane proteins, drug efflux transporters, in the BBB. Specific BSHPs to be attached to the surface of the Nanogel and target delivery to the BBB have been selected in vivo from a vast amount of peptides in the phage display library. Nanogel is non-toxic and highly effective as a transfection agent in many cell lines and evidently, one of the carriers with great potential for systemic administration. The vectorized RNA Interference-Producing system (RIP system) could be used for bioengineering of the BBB permeability for therapeutic agents whose brain accessibility was hampered by specific drug efflux transporters. The central hypothesis of the proposal is that transient suppression of selected drug efflux transporters in the BBB via systemic transfection of brain endothelium using targeted RNAi-producing systems can result in significant enhancement of drug transport to the brain during chemotherapy of the CNS-related diseases.
Our Specific aim 1 is to develop the BCEC-targeted Nanogel carriers for systemic delivery of plasmid DNA to the BBB.
Specific aim 2 is the enhance transfection efficacy of the BCEC-targeted Nanogel carriers in vitro and in vivo.
Specific aim 3 is to suppress selected drug efflux transporters in the BBB in vivo and temporary increase drug transport into the brain. In this Aim brain transport of several representive nucleoside analogue drugs will be assessed in animal model following the transient downregulation of drug efflux transporters in the BBB by the Nanogel-based RNAi-producing systems. ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
1R01NS050660-01A1
Application #
6972939
Study Section
Special Emphasis Panel (ZRG1-MDCN-C (54))
Program Officer
Pancrazio, Joseph J
Project Start
2005-07-01
Project End
2009-06-30
Budget Start
2005-07-01
Budget End
2006-06-30
Support Year
1
Fiscal Year
2005
Total Cost
$227,088
Indirect Cost
Name
University of Nebraska Medical Center
Department
Other Basic Sciences
Type
Schools of Pharmacy
DUNS #
168559177
City
Omaha
State
NE
Country
United States
Zip Code
68198
Ambardekar, Vishakha V; Han, Huai-Yun; Varney, Michelle L et al. (2011) The modification of siRNA with 3' cholesterol to increase nuclease protection and suppression of native mRNA by select siRNA polyplexes. Biomaterials 32:1404-11
Zhang, Hongwei; Gerson, Trevor; Varney, Michelle L et al. (2010) Multifunctional peptide-PEG intercalating conjugates: programmatic of gene delivery to the blood-brain barrier. Pharm Res 27:2528-43
Vinogradov, Serguei V (2010) Nanogels in the race for drug delivery. Nanomedicine (Lond) 5:165-8
Zhang, Hongwei; Vinogradov, Serguei V (2010) Short biodegradable polyamines for gene delivery and transfection of brain capillary endothelial cells. J Control Release 143:359-66
Zhang, Hongwei; Mitin, Anton; Vinogradov, Serguei V (2009) Efficient transfection of blood-brain barrier endothelial cells by lipoplexes and polyplexes in the presence of nuclear targeting NLS-PEG-acridine conjugates. Bioconjug Chem 20:120-8
Kabanov, Alexander V; Vinogradov, Serguei V (2009) Nanogels as pharmaceutical carriers: finite networks of infinite capabilities. Angew Chem Int Ed Engl 48:5418-29
Vinogradov, Serguei V; Zhang, Hongwei; Mitin, Anton et al. (2008) INTERCALATING CONJUGATES OF PEG WITH NUCLEAR LOCALIZATION SIGNAL (NLS) PEPTIDE. Polymer Prepr 49:434-435
Vinogradov, Serguei V (2007) Polymeric nanogel formulations of nucleoside analogs. Expert Opin Drug Deliv 4:5-17
Vinogradov, Serguei V; Kohli, Ekta; Zeman, Arin et al. (2006) Chemical engineering of nanogel drug carriers: increased bioavailability and decreased cytotoxicity. Polymer Prepr 47:27-28
Vinogradov, Serguei V (2006) Colloidal microgels in drug delivery applications. Curr Pharm Des 12:4703-12